Success Metrics

Clinical Success Rate
76.5%

Based on 13 completed trials

Completion Rate
76%(13/17)
Active Trials
5(21%)
Results Posted
123%(16 trials)
Terminated
4(17%)

Phase Distribution

Ph early_phase_1
2
8%
Ph phase_3
7
29%
Ph phase_2
9
38%
Ph phase_4
6
25%

Phase Distribution

2

Early Stage

9

Mid Stage

13

Late Stage

Phase Distribution24 total trials
Early Phase 1First-in-human
2(8.3%)
Phase 2Efficacy & side effects
9(37.5%)
Phase 3Large-scale testing
7(29.2%)
Phase 4Post-market surveillance
6(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

68.4%

13 of 19 finished

Non-Completion Rate

31.6%

6 ended early

Currently Active

5

trials recruiting

Total Trials

24

all time

Status Distribution
Active(5)
Completed(13)
Terminated(6)

Detailed Status

Completed13
Recruiting5
Terminated4
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
24
Active
5
Success Rate
76.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (8.3%)
Phase 29 (37.5%)
Phase 37 (29.2%)
Phase 46 (25.0%)

Trials by Status

recruiting521%
withdrawn28%
terminated417%
completed1354%

Recent Activity

Clinical Trials (24)

Showing 20 of 24 trialsScroll for more
NCT05441280Phase 2

Pimavanserin for Insomnia in Veterans With PTSD

Recruiting
NCT05555615Phase 2

Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder

Terminated
NCT05590637Phase 4

Comparing Antipsychotic Medications in LBD Over Time

Recruiting
NCT04373317Phase 4

Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

Recruiting
NCT03121586Phase 3

Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

Terminated
NCT05523895Phase 2

Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder

Completed
NCT04531982Phase 3

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia

Completed
NCT05357612Phase 4

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Recruiting
NCT06592833Phase 2

Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder

Recruiting
NCT04292223Phase 4

Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

Completed
NCT03575052Phase 3

A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Completed
NCT05796167Early Phase 1

Pimavanserin for Sleep in Parkinson Disease

Withdrawn
NCT03623321Phase 3

Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Completed
NCT04809116Phase 4

Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder: Proof of Concept

Withdrawn
NCT04188392Phase 4

Pimavanserin for Insomnia In Veterans With Posttraumatic Stress Disorder

Completed
NCT04000009Phase 3

Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Terminated
NCT03968159Phase 3

Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Completed
NCT04164758Phase 2

Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

Terminated
NCT04794413Early Phase 1

Pimavanserin Treatment in TS

Completed
NCT02970305Phase 2

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
24